European Commission Announces Marketing Authorisation For 50mg Once Weekly Enbrel(R) For Patients With Moderate-To-Severe Psoriasis
The European Commission announced a new 50mg Enbrel® (etanercept) once weekly dosage regimen as an alternative to the currently approved 25mg Enbrel® twice weekly regimen for the treatment of patients with moderate-to-severe plaque psoriasis. Based on the outcome of the extensive European
Original post by Women’s Health / Gynecology News From Medical News Today
Related Articles
Abbott’s HUMIRA® Approved In The European Union For Treatment Of Moderate To Severe Plaque Psoriasis New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate To Severe Plaque Psoriasis In Children And Adolescents Abbott’s HUMIRA® Receives Positive Opinion From EMEA For Treatment Of Moderate To Severe Plaque Psoriasis Abbott’s HUMIRA(R) Receives Positive Opinion From EMEA For Treatment Of Moderate To Severe Plaque Psoriasis New Findings Show Enbrel Significantly Reduced Levels Of C-reactive Protein
